top of page

BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year

Nov 5, 2024
1 min read

CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein called S100A4. It recently had P1 data in healthy volunteers and psoriasis patients, and will be advancing to two phase 2s in IPF and systemic sclerosis next year.



Brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@Biotech.TV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page